title: [Relationship between cysteinyl leukotriene in exhaled breath condensate and the severity of asthma in adult asthmatics in Japan].
abstract: BACKGROUND
  The measurement of several mediators in exhaled breath condensate (EBC) can be useful as the biomarker for asthma. But there are a few reports about EBC of asthmatics in Japan.
  
  
  OBJECTIVE
  We examined the safety of the collection of EBC and the utility of cysteinyl leukotriene (cysLTs) in EBC as the biomarker of asthma.
  
  
  METHODS
  Fifty-three asthmatics and eleven subjects without asthma were recruited. After the measuring of exhaled nitric oxide (eNO) and spirometory, EBC were collected. The levels of cysLTs in EBC were measurement by ELISA within 2 months.
  
  
  RESULTS
  The collection of EBC did not induce any other symptoms in all subjects. In 48 subjects, the collection significantly increased their FEV1 and MMF level (DeltaFEV1: 2.27+/-0.77%, DeltaMMF 14.6+/-3.92% (mean+/-SEM). The level of cysLTs in EBC on asthmatics treated with high-dose ICS was significantly high compared with control group (p=0.0034), steroid-naïve asthmatics or asthmatics treated with low-dose ICS (steroid naive vs. high dose ICS, p=0.041, low dose ICS vs. high dose ICS, p=0.021). The relationship between cysLTs in EBC and the levels of LTE4 in urine was significantly correlated (n=34, r=0.32, p=0.0435). The relationship between cysLTs in EBC and the levels of eNO was significantly correlated only in steroid-naïve asthmatics (r=-0.57, p=0.0369). There was no relationship between cysLTs in EBC and FEV1, or log PC20Ach.
  
  
  CONCLUSIONS
  The collection of EBC was perfectly non-invasive. The level of cysLTs can be useful as a biomarker of asthma.
authors: Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital. t-tuburai@Sagamihara-hosp.gr.jp
authors: Takahiro
authors: T
authors: Tsuburai
authors: Haruhisa
authors: H
authors: Mita
authors: Naomi
authors: N
authors: Tsurikisawa
authors: Chiyako
authors: C
authors: Oshikata
authors: Emiko
authors: E
authors: Ono
authors: Yuma
authors: Y
authors: Fukutomi
authors: Hidenori
authors: H
authors: Tanimoto
authors: Kiyoshi
authors: K
authors: Sekiya
authors: Mamoru
authors: M
authors: Otomo
authors: Yuji
authors: Y
authors: Maeda
authors: Masami
authors: M
authors: Taniguchi
authors: Kunihiko
authors: K
authors: Ikehara
authors: Kazuo
authors: K
authors: Akiyama
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D001249:Asthma / Q000175:diagnosis* / Q000188:drug therapy; D015415:Biomarkers / Q000032:analysis*; D001944:Breath Tests; D003545:Cysteine / Q000032:analysis*; D005260:Female; D006801:Humans; D007564:Japan; D015289:Leukotrienes / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000032:analysis; D012720:Severity of Illness Index
chemical_list: D000305:Adrenal Cortex Hormones; D015415:Biomarkers; D015289:Leukotrienes; C112381:cysteinyl-leukotriene; D009569:Nitric Oxide; D003545:Cysteine